Susquehanna International Group, LLP Prothena Corp Public LTD CO Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

28 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$16.73 - $24.79 $965,321 - $1.43 Million	57,700 Added 104.53%	112,900 $1.89 Million
Q2 2024 Aug 15, 2024	SELL	$19.54 - $26.15 $580,338 - $776,655	-29,700 Reduced 34.98%	55,200 $1.14 Million
Q1 2024 May 07, 2024	SELL	$24.75 - $40.66 $11.3 Million - $18.6 Million	-456,600 Reduced 84.32%	84,900 $2.1 Million
Q4 2023 Feb 14, 2024	BUY	$32.31 - $52.32 $16.1 Million - $26.1 Million	498,800 Added 1168.15%	541,500 $19.7 Million
Q3 2023 Nov 14, 2023	SELL	$47.3 - $70.6 $3.9 Million - $5.82 Million	-82,400 Reduced 65.87%	42,700 $2.06 Million
Q2 2023 Aug 11, 2023	BUY	$48.26 - $78.59 $1.74 Million - $2.83 Million	36,000 Added 40.4%	125,100 $8.54 Million
Q1 2023 May 16, 2023	SELL	$46.97 - $58.27 $591,822 - $734,202	-12,600 Reduced 12.39%	89,100 $4.32 Million
Q4 2022 Feb 14, 2023	SELL	$52.05 - $65.0 $1.23 Million - $1.53 Million	-23,600 Reduced 18.83%	101,700 $6.13 Million
Q3 2022 Nov 14, 2022	SELL	$25.16 - $60.63 $395,012 - $951,891	-15,700 Reduced 11.13%	125,300 $7.6 Million
Q2 2022 Aug 15, 2022	BUY	$22.73 - $39.98 $2.4 Million - $4.22 Million	105,600 Added 298.31%	141,000 $3.83 Million
Q1 2022 May 16, 2022	SELL	$30.27 - $49.22 $1.76 Million - $2.87 Million	-58,300 Reduced 62.22%	35,400 $1.3 Million
Q4 2021 Feb 14, 2022	SELL	$42.11 - $73.26 $661,127 - $1.15 Million	-15,700 Reduced 14.35%	93,700 $4.63 Million
Q3 2021 Nov 15, 2021	BUY	$48.2 - $78.89 $1.39 Million - $2.27 Million	28,800 Added 35.73%	109,400 $7.79 Million
Q2 2021 Aug 11, 2021	SELL	$21.63 - $57.65 $1.52 Million - $4.06 Million	-70,400 Reduced 46.62%	80,600 $4.14 Million
Q1 2021 May 17, 2021	BUY	$11.0 - $28.24 $809,600 - $2.08 Million	73,600 Added 95.09%	151,000 $3.79 Million
Q4 2020 Feb 16, 2021	BUY	$10.12 - $13.94 $516,119 - $710,940	51,000 Added 193.18%	77,400 $930,000
Q3 2020 Nov 16, 2020	SELL	$9.93 - $13.47 $244,278 - $331,362	-24,600 Reduced 48.24%	26,400 $264,000
Q1 2020 May 15, 2020	BUY	$7.54 - $15.77 $105,560 - $220,780	14,000 Added 37.84%	51,000 $546,000
Q4 2019 Feb 14, 2020	SELL	$7.48 - $17.01 $352,308 - $801,171	-47,100 Reduced 56.0%	37,000 $586,000
Q3 2019 Nov 14, 2019	BUY	$6.89 - $10.45 $451,984 - $685,520	65,600 Added 354.59%	84,100 $659,000
Q2 2019 Aug 14, 2019	SELL	$8.85 - $12.49 $92,925 - $131,145	-10,500 Reduced 36.21%	18,500 $196,000
Q1 2019 May 15, 2019	SELL	$10.32 - $14.49 $383,904 - $539,028	-37,200 Reduced 56.19%	29,000 $352,000
Q4 2018 Feb 14, 2019	SELL	$8.73 - $13.74 $70,713 - $111,294	-8,100 Reduced 10.9%	66,200 $682,000
Q3 2018 Nov 14, 2018	SELL	$12.7 - $15.79 $74,930 - $93,161	-5,900 Reduced 7.36%	74,300 $972,000
Q2 2018 Aug 14, 2018	SELL	$10.99 - $44.21 $1.79 Million - $7.19 Million	-162,700 Reduced 66.98%	80,200 $1.17 Million
Q1 2018 May 15, 2018	BUY	$27.95 - $45.04 $5.28 Million - $8.5 Million	188,800 Added 348.98%	242,900 $8.92 Million
Q4 2017 Feb 14, 2018	BUY	$35.44 - $63.76 $528,056 - $950,024	14,900 Added 38.01%	54,100 $2.03 Million
Q3 2017 Nov 14, 2017	BUY	$53.83 - $67.75 $2.11 Million - $2.66 Million	39,200	39,200 $2.54 Million

Others Institutions Holding PRTA

# of Institutions

184

Shares Held

42.7M

Call Options Held

162K

Put Options Held

102K

Eco R1 Capital, LLC San Francisco, CA

11.6M
Shares

$162 Million
8.41% of portfolio
Wellington Management Group LLP Boston, MA

4.18M
Shares

$58.5 Million
0.01% of portfolio
Black Rock Inc. New York, NY

3.86M
Shares

$54 Million
0.0% of portfolio
Price T Rowe Associates Inc Baltimore, MD

3.82M
Shares

$53.6 Million
0.01% of portfolio
Palo Alto Investors LP Palo Alto, CA

1.74M
Shares

$24.3 Million
4.0% of portfolio

View Full List

About PROTHENA CORP PUBLIC LTD CO

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $657M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

More about PRTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account